Annexin Pharmaceuticals AB (ANNX) - Total Assets
Based on the latest financial reports, Annexin Pharmaceuticals AB (ANNX) holds total assets worth Skr19.98 Million SEK (≈ $2.15 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Annexin Pharmaceuticals AB to assess how comfortably operating cash covers total debt obligations.
Annexin Pharmaceuticals AB - Total Assets Trend (2014–2025)
This chart illustrates how Annexin Pharmaceuticals AB's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Annexin Pharmaceuticals AB for net asset value and shareholders' equity analysis.
Annexin Pharmaceuticals AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Annexin Pharmaceuticals AB's total assets of Skr19.98 Million consist of 94.7% current assets and 5.3% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 90.8% |
| Accounts Receivable | Skr376.00K | 1.3% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr1.12 Million | 3.7% |
| Intangible Assets | Skr164.00K | 0.5% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Annexin Pharmaceuticals AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Annexin Pharmaceuticals AB market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Annexin Pharmaceuticals AB's current assets represent 94.7% of total assets in 2025, an increase from 55.1% in 2014.
- Cash Position: Cash and equivalents constituted 90.8% of total assets in 2025, up from 49.7% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 42.0% in 2014.
- Asset Diversification: The largest asset category is property, plant & equipment at 3.7% of total assets.
Annexin Pharmaceuticals AB Competitors by Total Assets
Key competitors of Annexin Pharmaceuticals AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
Annexin Pharmaceuticals AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.31 | 9.04 | 5.51 |
| Quick Ratio | 3.31 | 9.04 | 5.55 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr12.87 Million | Skr41.27 Million | Skr15.36 Million |
Annexin Pharmaceuticals AB - Advanced Valuation Insights
This section examines the relationship between Annexin Pharmaceuticals AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.32 |
| Latest Market Cap to Assets Ratio | 0.30 |
| Asset Growth Rate (YoY) | 58.4% |
| Total Assets | Skr30.16 Million |
| Market Capitalization | $9.15 Million USD |
Valuation Analysis
Below Book Valuation: The market values Annexin Pharmaceuticals AB's assets below their book value (0.30x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Annexin Pharmaceuticals AB's assets grew by 58.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Annexin Pharmaceuticals AB (2014–2025)
The table below shows the annual total assets of Annexin Pharmaceuticals AB from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr30.16 Million ≈ $3.25 Million |
+58.42% |
| 2024-12-31 | Skr19.04 Million ≈ $2.05 Million |
-28.87% |
| 2023-12-31 | Skr26.76 Million ≈ $2.88 Million |
-27.03% |
| 2022-12-31 | Skr36.68 Million ≈ $3.95 Million |
-30.51% |
| 2021-12-31 | Skr52.79 Million ≈ $5.68 Million |
+109.82% |
| 2020-12-31 | Skr25.16 Million ≈ $2.71 Million |
+56.88% |
| 2019-12-31 | Skr16.04 Million ≈ $1.73 Million |
-65.17% |
| 2018-12-31 | Skr46.04 Million ≈ $4.95 Million |
+49.24% |
| 2017-12-31 | Skr30.85 Million ≈ $3.32 Million |
+31.50% |
| 2016-12-31 | Skr23.46 Million ≈ $2.52 Million |
+645.68% |
| 2015-12-31 | Skr3.15 Million ≈ $338.56K |
-14.75% |
| 2014-12-31 | Skr3.69 Million ≈ $397.16K |
-- |
About Annexin Pharmaceuticals AB
Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions that is in phase 2 clinical phase for the treatment of ophthalmo… Read more